- Home
- PSHG vs LGVN Comparison
PSHG vs LGVN Comparison
Compare PSHG & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSHG
- LGVN
- Stock Information
- Founded
- PSHG 2010
- LGVN 2014
- Country
- PSHG Greece
- LGVN United States
- Employees
- PSHG N/A
- LGVN N/A
- Industry
- PSHG Marine Transportation
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- PSHG Consumer Discretionary
- LGVN Health Care
- Exchange
- PSHG Nasdaq
- LGVN Nasdaq
- Market Cap
- PSHG 20.8M
- LGVN 23.4M
- IPO Year
- PSHG N/A
- LGVN 2021
- Fundamental
- Price
- PSHG $1.72
- LGVN $1.30
- Analyst Decision
- PSHG Strong Buy
- LGVN Strong Buy
- Analyst Count
- PSHG 1
- LGVN 3
- Target Price
- PSHG $6.50
- LGVN $8.67
- AVG Volume (30 Days)
- PSHG 191.8K
- LGVN 150.1K
- Earning Date
- PSHG 07-24-2025
- LGVN 08-13-2025
- Dividend Yield
- PSHG N/A
- LGVN N/A
- EPS Growth
- PSHG N/A
- LGVN N/A
- EPS
- PSHG 1.58
- LGVN N/A
- Revenue
- PSHG $86,407,000.00
- LGVN $2,225,000.00
- Revenue This Year
- PSHG N/A
- LGVN N/A
- Revenue Next Year
- PSHG $23.25
- LGVN $51.48
- P/E Ratio
- PSHG $1.08
- LGVN N/A
- Revenue Growth
- PSHG N/A
- LGVN 127.50
- 52 Week Low
- PSHG $1.31
- LGVN $1.14
- 52 Week High
- PSHG $2.34
- LGVN $6.40
- Technical
- Relative Strength Index (RSI)
- PSHG 48.43
- LGVN 50.50
- Support Level
- PSHG $1.75
- LGVN $1.15
- Resistance Level
- PSHG $1.90
- LGVN $1.40
- Average True Range (ATR)
- PSHG 0.15
- LGVN 0.09
- MACD
- PSHG -0.03
- LGVN 0.01
- Stochastic Oscillator
- PSHG 7.46
- LGVN 46.87
About PSHG Performance Shipping Inc.
Performance Shipping Inc is a provider of shipping transportation services through its ownership of tanker vessels. The company's vessels are employed on time charters with liner companies carrying containerized cargo along various shipping routes. It owns and operates six Aframax tanker vessels.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.